ID   EoL-1
AC   CVCL_0258
SY   EOL-1; EOL1; EoL-1-cell; EoL-1 cell; AML-EOL-1
DR   BTO; BTO:0002405
DR   CLO; CLO_0002932
DR   CLO; CLO_0002933
DR   CLO; CLO_0050996
DR   MCCL; MCC:0000149
DR   CLDB; cl1166
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioGRID_ORCS_Cell_line; 209
DR   BioSample; SAMN01821624
DR   BioSample; SAMN03473158
DR   BioSample; SAMN10988490
DR   cancercelllines; CVCL_0258
DR   Cell_Model_Passport; SIDM00277
DR   ChEMBL-Cells; CHEMBL3308381
DR   ChEMBL-Targets; CHEMBL614489
DR   Cosmic; 787428
DR   Cosmic; 798671
DR   Cosmic; 906856
DR   Cosmic; 975246
DR   Cosmic; 994180
DR   Cosmic; 999731
DR   Cosmic; 1012065
DR   Cosmic; 1278780
DR   Cosmic; 1623638
DR   Cosmic; 2131562
DR   Cosmic-CLP; 906856
DR   DepMap; ACH-000198
DR   DSMZ; ACC-386
DR   DSMZCellDive; ACC-386
DR   ECACC; 94042252
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 906856
DR   GEO; GSM887006
DR   GEO; GSM888075
DR   GEO; GSM1374475
DR   GEO; GSM1446733
DR   GEO; GSM1669766
DR   IARC_TP53; 21331
DR   IARC_TP53; 30032
DR   LiGeA; CCLE_554
DR   PharmacoDB; EoL1cell_335_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0258
DR   PubChem_Cell_line; CVCL_0258
DR   RCB; RCB0641
DR   RCB; RCB3679
DR   TKG; TKG 0476
DR   Wikidata; Q54832338
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   DOI=10.11418/jtca1981.15.4_211;
RX   PubMed=1477652;
RX   PubMed=2415185;
RX   PubMed=8558913;
RX   PubMed=14630792;
RX   PubMed=14671638;
RX   PubMed=15843827;
RX   PubMed=16408098;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: ~60 hours (DSMZ=ACC-386).
CC   HLA typing: A*24:02,29:02; B*35:03,44:03; C*04:01,16:01 (PubMed=26589293).
CC   HLA typing: A*24:02:01,29:02:01; B*35:03:01,44:03:01; C*04:01:01,16:01:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,02:01:02; DQA1*03:03:01,03:03:01; DQB1*03:01:01,03:01:01; DRA*01:01:01,01:02:02; DRB1*04:07:01,12:01:01 (DSMZCellDive=ACC-386).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 19124; FIP1L1 + HGNC; 8803; PDGFRA; Name(s)=FIP1L1-PDGFRA (PubMed=14630792).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.14%; Native American=0%; East Asian, North=2.93%; East Asian, South=0%; South Asian=0%; European, North=52.17%; European, South=43.75% (PubMed=30894373).
CC   Discontinued: RCB; RCB3679; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): Cosmic-CLP; DSMZ; ECACC; PubMed=25877200; RCB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 7,10
ST   D13S317: 12,13
ST   D16S539: 8,10
ST   D18S51: 12,14
ST   D19S433: 12,13
ST   D21S11: 29
ST   D2S1338: 17,18
ST   D3S1358: 16,17
ST   D5S818: 11
ST   D7S820: 10,13
ST   D8S1179: 13
ST   FGA: 24
ST   Penta D: 7,10,11 (DSMZ)
ST   Penta D: 7,11 (PubMed=25877200)
ST   Penta E: 5,7
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C4563; Chronic eosinophilic leukemia, not otherwise specified
DI   ORDO; Orphanet_168940; Chronic eosinophilic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_S960 ! EoL-2
OI   CVCL_4069 ! EoL-3
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   DOI=10.11418/jtca1981.15.4_211;
RA   Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.;
RT   "Identification of cell lines with variable numbers of tandem repeat
RT   (VNTR) amplified by polymerase chain reaction.";
RL   Tissue Cult. Res. Commun. 15:211-219(1996).
//
RX   PubMed=1477652; DOI=10.3109/10428199209053629;
RA   Mayumi M.;
RT   "EoL-1, a human eosinophilic cell line.";
RL   Leuk. Lymphoma 7:243-250(1992).
//
RX   PubMed=2415185; DOI=10.1182/blood.V66.6.1233.1233;
RA   Saito H., Bourinbaiar A.S., Ginsburg M., Minato K., Ceresi E.,
RA   Yamada K., Machover D., Breard J., Mathe G.;
RT   "Establishment and characterization of a new human eosinophilic
RT   leukemia cell line.";
RL   Blood 66:1233-1240(1985).
//
RX   PubMed=8558913;
RA   Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M.,
RA   Imaizumi M., Endo M., Takano N., Konno T.;
RT   "Cell surface c-kit receptors in human leukemia cell lines and
RT   pediatric leukemia: selective preservation of c-kit expression on
RT   megakaryoblastic cell lines during adaptation to in vitro culture.";
RL   Leukemia 10:102-105(1996).
//
RX   PubMed=14630792; DOI=10.1182/blood-2003-07-2479;
RA   Cools J., Quentmeier H., Huntly B.J.P., Marynen P., Griffin J.D.,
RA   Drexler H.G., Gilliland D.G.;
RT   "The EOL-1 cell line as an in vitro model for the study of
RT   FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.";
RL   Blood 103:2802-2805(2004).
//
RX   PubMed=14671638; DOI=10.1038/sj.leu.2403236;
RA   Drexler H.G., Quentmeier H., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   MLL gene alterations.";
RL   Leukemia 18:227-232(2004).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//